• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Jan. 6, 2016

View Archived Issues

Insulin non-shock: Sluggish launch of Afrezza sours Mannkind's Sanofi deal, rights returning

Sanofi SA's decision to hand back rights added another chapter to the saga of Mannkind Corp. with inhaled insulin Afrezza, but the hard-hit biotech firm's chief financial officer, Matthew Pfeffer, said the quit is "not the end of the line for Afrezza or Mannkind, by any means." Read More

Petra 'accelerates' into $48M series A to tackle cancer, metabolic disease

Petra Pharma Corp. became the first life science start-up for the 1-year-old New York arm of Accelerator Corp., initially established more than a dozen years ago in Seattle. Read More

Acacia's new-mechanism anti-emetic nine months from NDA, says CEO

LONDON – Acacia Pharma Group plc reported positive results in a 1,200-patient phase III study of APD421, showing the anti-emetic reduced the relative risk of postoperative nausea and vomiting (PONV) by 22 percent when administered in combination with standard-of-care anti-emetics. Read More

GPhA shines light on shady REMS and distribution practices

Taking advantage of the spotlight of public ire over escalating drug prices, generic drugmakers have joined forces with pharmacists and others to illuminate, and end, what they consider a shady practice to protect brand therapies from follow-on competition. Read More

Millendo raises $62M to advance in-licensed Astrazeneca endocrine disease therapy

Millendo Therapeutics Inc., financed with a new $62 million series B investment led by New Enterprise Associates (NEA), has exclusively licensed rights to develop and commercialize MLE4901, a phase II neurokinin 3 receptor antagonist licensed from Astrazeneca plc for the treatment of polycystic ovary syndrome. Read More

Annapurna in-licenses three Weill Cornell gene therapy programs

DUBLIN – Gene therapy pioneer Ron Crystal, of Weill Cornell Medical College, is deepening his involvement in Annapurna Therapeutics SAS (formerly AAVLife SAS), the French gene therapy firm he co-founded, by licensing to the company three development programs that are already under way at Weill Cornell's Department of Genetic Medicine. Read More

Yisheng looking to Singapore for initial rabies vaccine launch

HONG KONG – Chinese vaccine developer Yisheng Biopharma Co. Ltd. is looking at Southeast Asian markets as the first big opportunity for the company's rabies vaccine, but any marketing will not happen for at least two years. Read More

Financings

Corvus Pharmaceuticals Inc., of Burlingame, Calif., filed an S-1 with the SEC seeking to raise up to $115 million in an IPO, including a 30-day option for underwriters to purchase an undisclosed number of additional shares to fill overallotments. Read More

Other news to note

Scancell Holdings plc, of Nottingham, U.K., reported the online publication of a full paper in Cancer Research describing the rationale behind its Moditope platform and the experimental results that support it. Read More

In the clinic

Sound Pharmaceuticals Inc., of Seattle, said it started enrollment in a phase Ib trial to test SPI-1005 in the treatment of Meniere's disease, or idiopathic endolymphatic hydrops, an inner ear disease that involves episodic vertigo, sensorineural hearing loss and tinnitus. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 6, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe